Skip to main content

LAURA trial: a new standard of care in unresectable stage III EGFRm NSCLC

Intervista a Suresh S. Ramalingam By 2 Giugno 2024No Comments
Congressi

Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated (EGFRm) NSCLC: we interviewed Suresh S. Ramalingam (Emory University School of Medicine – Emory Winship Cancer Institute, Atlanta) about the primary results of the Phase 3 LAURA study during the ASCO congress 2024 in Chicago.